See what the data shows before the earnings call doesThe Market Already Moved. Did You See It Coming?
The market has priced in obesity and diabetes. The next GLP-1 opportunities are in the adjacent markets — the ones that won’t appear in financial reporting until the shift is already over.
Komodo Market Signals is a monthly briefing that shows, in concrete terms, how real-world patient data surfaces treatment shifts before they reach quarterly reporting. Each edition is a live example of the signals the data makes visible.
One briefing per month. No cost. Unsubscribe anytime. For informational purposes only. Does not constitute investment advice.
Get Komodo Market Signals
See Healthcare Market Shifts Before Earnings
Hedge funds and institutional investors use Komodo’s real-world patient data to detect treatment shifts before they show up in quarterly results.
Your Data Sources Were Built for Someone Else’s Questions
Claims data misses the medical benefit side. Syndicated reports run six months behind. Physician surveys capture intent, not behavior. By the time any of them confirm a shift, the trade has already been made.
The Same Data Life Sciences Uses for Launch Decisions
Komodo covers the majority of the U.S. healthcare system. 330M+ patient journeys, updated daily. Komodo Market Signals shows what that data reveals for investors before it shows up in quarterly reporting.
One Finding Per Month. Before It Reaches Consensus
Each edition surfaces one treatment shift that has not reached guidance yet. In Edition 2: GLP-1 adoption in PCOS grew 564% across 1M+ newly diagnosed patients. Generalists are displacing specialists. Observable now, not next quarter.
The Data Behind Every Answer
The real-world patient data foundation healchare decisions are built on.
See What the Data Show, Before the Earnings Call Does
Each month, one finding. One treatment shift that hasn’t reached consensus yet.
One email per month. No cost. Does not constitute investment advice.